Roquefort Therapeutics (ROQ) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Nov 2024 07:00 AM
RNS
Conversion of Convertible Loan Notes
06 Nov 2024 07:00 AM
RNS
STAT-6 siRNA Presentation
27 Sep 2024 07:00 AM
RNS
Interim Results to 30 June 2024
23 Sep 2024 07:00 AM
RNS
Grant of Japan MK Cell Patent
19 Sep 2024 07:00 AM
RNS
STAT-6 siRNA Demonstrates Efficacy in Immunology
02 Sep 2024 07:00 AM
RNS
Grant of MK Cell Patent & Licencing Update
27 Jun 2024 12:46 PM
RNS
Results of AGM
20 Jun 2024 07:00 AM
RNS
Appointment of Broker
04 Jun 2024 07:00 AM
RNS
Notice of Annual General Meeting
23 May 2024 07:05 AM
RNS
Issue of Convertible Loan Notes & Board Changes
23 May 2024 07:00 AM
RNS
Midkine Antibody Licencing Deal
26 Apr 2024 07:00 AM
RNS
Annual Report & Financial Statements - 31 Dec 2023
05 Apr 2024 07:00 AM
RNS
Response to Share Price Movement
11 Mar 2024 07:00 AM
RNS
Positive Results: Midkine mRNA and STAT-6 siRNA
06 Feb 2024 07:00 AM
RNS
Operations Update
24 Nov 2023 07:00 AM
RNS
Change of Auditor
06 Nov 2023 07:00 AM
RNS
Significant Mesodermal Killer Cell Milestone
27 Sep 2023 07:00 AM
RNS
Interim Results to 30 June 2023
22 Sep 2023 11:42 AM
RNS
Investor Presentation via Investor Meet Company
14 Aug 2023 07:00 AM
RNS
Expansion of Patent Portfolio
07 Aug 2023 07:00 AM
RNS
Development of New Novel siRNA Therapeutics
02 Aug 2023 07:00 AM
RNS
Director/PDMR Shareholding
12 Jul 2023 10:27 AM
RNS
Director/PDMR Shareholding
29 Jun 2023 10:05 AM
RNS
Results of AGM
29 Jun 2023 07:00 AM
RNS
AGM Statement
27 Jun 2023 07:00 AM
RNS
Investor Presentation via Investor Meet Company
26 Jun 2023 02:41 PM
RNS
Director/PDMR Shareholding
26 Jun 2023 10:36 AM
RNS
Director/PDMR Shareholding
26 Jun 2023 10:00 AM
RNS
Director/PDMR Shareholding
22 Jun 2023 07:00 AM
RNS
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
19 Jun 2023 07:00 AM
RNS
Antibody Program Results & Orphan Drug Indication
13 Jun 2023 07:00 AM
RNS
Anti-Cancer MDK mRNA - Positive in vitro Results
07 Jun 2023 10:11 AM
RNS
Restoration of Trading
06 Jun 2023 07:00 AM
RNS
Notice of Annual General Meeting
05 Jun 2023 07:00 AM
RNS
Annual Report & Financial Statements - 31 Dec 2022
02 May 2023 07:56 AM
RNS
Suspension of Trading Pending 2022 Annual Report
13 Mar 2023 07:30 AM
RNS
Confirmation of No Exposure to Silicon Valley Bank
08 Mar 2023 07:00 AM
RNS
Creation of New Novel Family of mRNA Therapeutics
06 Mar 2023 07:00 AM
RNS
Formation of Scientific Advisory Board
01 Mar 2023 07:00 AM
RNS
Company Presentation
21 Feb 2023 07:00 AM
RNS
Investor Presentation
20 Feb 2023 07:00 AM
RNS
Randox Licence and Royalty Agreement
24 Jan 2023 07:00 AM
RNS
MDK Oncology Antibodies Demonstrate In-Vivo Safety
18 Jan 2023 08:36 AM
RNS
Holding(s) in Company
16 Jan 2023 07:00 AM
RNS
Appointment of Auditor
09 Jan 2023 07:00 AM
RNS
Operations Update
05 Dec 2022 08:07 AM
RNS
Presentation of Midkine Oligonucleotide Program
01 Dec 2022 02:00 PM
RNS
Resignation of Auditor
25 Oct 2022 07:00 AM
RNS
Midkine Antibody Program - Festival of Biologics
11 Oct 2022 07:00 AM
RNS
ROQ Presents Study Results at the ESGCT Conference
UK 100